128 related articles for article (PubMed ID: 9408856)
1. Pharmacokinetic analysis of mizolastine in healthy young volunteers after single oral and intravenous doses: noncompartmental approach and compartmental modeling.
Mesnil F; Dubruc C; Mentre F; Huet S; Mallet A; Thenot JP
J Pharmacokinet Biopharm; 1997 Apr; 25(2):125-47. PubMed ID: 9408856
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
Deschamps C; Dubruc C; Mentre F; Rosenzweig P
Clin Pharmacol Ther; 2000 Dec; 68(6):647-57. PubMed ID: 11180025
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of mizolastine.
Lebrun-Vignes B; Diquet B; Chosidow O
Clin Pharmacokinet; 2001; 40(7):501-7. PubMed ID: 11510627
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children.
Mentré F; Dubruc C; Thénot JP
J Pharmacokinet Pharmacodyn; 2001 Jun; 28(3):299-319. PubMed ID: 11468942
[TBL] [Abstract][Full Text] [Related]
5. Plasma and skin suction-blister-fluid pharmacokinetics and time course of the effects of oral mizolastine.
Chosidow O; Dubruc C; Danjou P; Fuseau E; Espagne E; Bianchetti G; Thenot JP; Herson S; Rosenzweig P; Revuz J
Eur J Clin Pharmacol; 1996; 50(4):327-33. PubMed ID: 8803528
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method.
Mesnil F; Mentré F; Dubruc C; Thénot JP; Mallet A
J Pharmacokinet Biopharm; 1998 Apr; 26(2):133-61. PubMed ID: 9795879
[TBL] [Abstract][Full Text] [Related]
7. Mizolastine: antihistaminic activity from preclinical data to clinical evaluation.
Simons FE
Clin Exp Allergy; 1999 Mar; 29 Suppl 1():3-8. PubMed ID: 10209699
[TBL] [Abstract][Full Text] [Related]
8. Lack of interaction between a new antihistamine, mizolastine, and lorazepam on psychomotor performance and memory in healthy volunteers.
Patat A; Perault MC; Vandel B; Ulliac N; Zieleniuk I; Rosenzweig P
Br J Clin Pharmacol; 1995 Jan; 39(1):31-8. PubMed ID: 7756096
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans.
Molimard M; Diquet B; Benedetti MS
Fundam Clin Pharmacol; 2004 Aug; 18(4):399-411. PubMed ID: 15312146
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine.
Rosenzweig P; Thebault JJ; Caplain H; Dubruc C; Bianchetti G; Fuseau E; Morselli PL
Ann Allergy; 1992 Aug; 69(2):135-9. PubMed ID: 1354949
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of histamine-induced skin wheal and flare after 5 days of mizolastine.
Pinquier JL; Caplain H; Cabanis MJ; Dubruc C; Stalla-Bourdillon A; Rosenzweig P
J Clin Pharmacol; 1996 Jan; 36(1):72-8. PubMed ID: 8932546
[TBL] [Abstract][Full Text] [Related]
12. Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1-receptor antagonist.
Chaufour S; Caplain H; Lilienthal N; L'héritier C; Deschamps C; Dubruc C; Rosenzweig P
Br J Clin Pharmacol; 1999 May; 47(5):515-20. PubMed ID: 10336575
[TBL] [Abstract][Full Text] [Related]
13. A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine.
Urien S; Tillement JP; Ganem B; Kuch MD
Int J Clin Pharmacol Ther; 1999 Oct; 37(10):499-502. PubMed ID: 10543317
[TBL] [Abstract][Full Text] [Related]
14. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
He YL; Sadler BM; Sabo R; Balez S; Wang Y; Campestrini J; Laurent A; Ligueros-Saylan M; Howard D
Clin Pharmacokinet; 2007; 46(9):787-802. PubMed ID: 17713976
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of an antiallergic agent, 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1, 4-diazepin-1-yl)-1H-benzimidazole difumarate (KG-2413) after oral administration: interspecies differences in rats, guinea pigs and dogs.
Sakai T; Hamada T; Awata N; Watanabe J
J Pharmacobiodyn; 1989 Sep; 12(9):530-6. PubMed ID: 2575663
[TBL] [Abstract][Full Text] [Related]
16. QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamine.
Delauche-Cavallier MC; Chaufour S; Guérault E; Lacroux A; Murrieta M; Wajman A
Clin Exp Allergy; 1999 Jul; 29 Suppl 3():206-11. PubMed ID: 10444239
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic properties of ethosuximide in monkeys. I. Single-dose intravenous and oral administration.
Patel IH; Levy RH; Bauer TG
Epilepsia; 1975 Dec; 16(5):705-16. PubMed ID: 816644
[TBL] [Abstract][Full Text] [Related]
18. Absorption kinetics of procainamide in humans.
Manion CV; Lalka D; Baer DT; Meyer MB
J Pharm Sci; 1977 Jul; 66(7):981-4. PubMed ID: 886461
[TBL] [Abstract][Full Text] [Related]
19. Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat.
Pichat P; Angel I; Arbilla S
Arzneimittelforschung; 1998 Feb; 48(2):173-8. PubMed ID: 9541729
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of emedastine difumarate, a new anti-histaminic agent in patients with renal impairment.
Joukhadar C; Herranz U; Pernerstorfer T; Assandri A; Klein N; Schrolnberger C; Lackner E; Eichler HG; Müller M
Eur J Clin Pharmacol; 2001 Mar; 56(12):905-10. PubMed ID: 11317479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
